IMC Chicago’s Regeneron Pharmaceuticals REGN Stock Holding History

IMC Chicago’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,952	Closed	-$10.2M	–	3832
2025 Q2	$9.42M	Buy	+17,952	New	+$10M	﹤0.01%	1041

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

IMC Chicago's REGN Position: Q3 2025 in Review

IMC Chicago sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 17,952 shares — an estimated $10.2M sold.

IMC Chicago first reported a position in REGN in Q2 2025 and held it in 1 quarter. The position peaked at $9.42M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

IMC Chicago reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
IMC Chicago sold 17,952 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $10.2M.
IMC Chicago first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 1 quarter.
IMC Chicago's Regeneron Pharmaceuticals position peaked at $9.42M in Q2 2025.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.